| Dr Ishita Sheth, MD | |
|
275 Collier Rd Nw Ste 450, Atlanta, GA 30309-1748 | |
| (718) 299-7295 | |
| (718) 299-7295 |
| Full Name | Dr Ishita Sheth |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Infectious Disease |
| Location | 275 Collier Rd Nw Ste 450, Atlanta, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598015547 | NPI | - | NPPES |
| 003273581A | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 92814 (Georgia) | Primary |
| Entity Name | Essen Medical Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366418709 PECOS PAC ID: 1759353501 Enrollment ID: O20040811000885 |
News Archive
Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.
Mylan Inc. today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Shionogi Pharma Inc. and CIMA LABS INC. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg and 30 mg.
The Wall Street Journal offers a collection of stories that looks at changes in health care that could yield big responses: "Health-care innovations come in many shapes and sizes ... [including] the kind that can help reach the goal that continues to elude our policy makers: getting good care to the greatest number of people in the most cost-effective way."
Scientists in the USA have established a way to predict outbreaks of cholera, making it easier to control. This finding could provide a model to predict and potentially control outbreaks of other important infectious diseases.
Netpulse, the only interactive media platform for fitness centers and active lifestyle consumers, announced today that it has secured $3.1 million in Series A funding led by Javelin Venture Partners with participation from DFJ Frontier.
› Verified 5 days ago
| Entity Name | House Call Medical Services Of New York Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851345946 PECOS PAC ID: 2264517754 Enrollment ID: O20080307000427 |
News Archive
Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.
Mylan Inc. today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Shionogi Pharma Inc. and CIMA LABS INC. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg and 30 mg.
The Wall Street Journal offers a collection of stories that looks at changes in health care that could yield big responses: "Health-care innovations come in many shapes and sizes ... [including] the kind that can help reach the goal that continues to elude our policy makers: getting good care to the greatest number of people in the most cost-effective way."
Scientists in the USA have established a way to predict outbreaks of cholera, making it easier to control. This finding could provide a model to predict and potentially control outbreaks of other important infectious diseases.
Netpulse, the only interactive media platform for fitness centers and active lifestyle consumers, announced today that it has secured $3.1 million in Series A funding led by Javelin Venture Partners with participation from DFJ Frontier.
› Verified 5 days ago
| Entity Name | Essen Medical Urgicare, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841607298 PECOS PAC ID: 4385960897 Enrollment ID: O20150227000903 |
News Archive
Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.
Mylan Inc. today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Shionogi Pharma Inc. and CIMA LABS INC. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg and 30 mg.
The Wall Street Journal offers a collection of stories that looks at changes in health care that could yield big responses: "Health-care innovations come in many shapes and sizes ... [including] the kind that can help reach the goal that continues to elude our policy makers: getting good care to the greatest number of people in the most cost-effective way."
Scientists in the USA have established a way to predict outbreaks of cholera, making it easier to control. This finding could provide a model to predict and potentially control outbreaks of other important infectious diseases.
Netpulse, the only interactive media platform for fitness centers and active lifestyle consumers, announced today that it has secured $3.1 million in Series A funding led by Javelin Venture Partners with participation from DFJ Frontier.
› Verified 5 days ago
| Entity Name | Bronx Medical Practice Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356726087 PECOS PAC ID: 9739496100 Enrollment ID: O20150917000004 |
News Archive
Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.
Mylan Inc. today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Shionogi Pharma Inc. and CIMA LABS INC. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg and 30 mg.
The Wall Street Journal offers a collection of stories that looks at changes in health care that could yield big responses: "Health-care innovations come in many shapes and sizes ... [including] the kind that can help reach the goal that continues to elude our policy makers: getting good care to the greatest number of people in the most cost-effective way."
Scientists in the USA have established a way to predict outbreaks of cholera, making it easier to control. This finding could provide a model to predict and potentially control outbreaks of other important infectious diseases.
Netpulse, the only interactive media platform for fitness centers and active lifestyle consumers, announced today that it has secured $3.1 million in Series A funding led by Javelin Venture Partners with participation from DFJ Frontier.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ishita Sheth, MD 275 Collier Rd Nw Ste 450, Atlanta, GA 30309-1748 Ph: (404) 355-3161 | Dr Ishita Sheth, MD 275 Collier Rd Nw Ste 450, Atlanta, GA 30309-1748 Ph: (718) 299-7295 |
News Archive
Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.
Mylan Inc. today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Shionogi Pharma Inc. and CIMA LABS INC. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg and 30 mg.
The Wall Street Journal offers a collection of stories that looks at changes in health care that could yield big responses: "Health-care innovations come in many shapes and sizes ... [including] the kind that can help reach the goal that continues to elude our policy makers: getting good care to the greatest number of people in the most cost-effective way."
Scientists in the USA have established a way to predict outbreaks of cholera, making it easier to control. This finding could provide a model to predict and potentially control outbreaks of other important infectious diseases.
Netpulse, the only interactive media platform for fitness centers and active lifestyle consumers, announced today that it has secured $3.1 million in Series A funding led by Javelin Venture Partners with participation from DFJ Frontier.
› Verified 5 days ago
Khadeja Jamilia Johnson, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1800 Howell Mill Rd Nw Ste 275, Atlanta, GA 30318 Phone: 404-756-1290 | |
Dr. Matthew J. Wilson, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 755 Mt Vernon Hwy, Suite 530, Atlanta, GA 30328 Phone: 404-252-7970 Fax: 404-250-0553 | |
Kajal Patel, M.D, M.P.H Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1525 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-778-2700 | |
Dr. Earl Stewart Jr., M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2850 Paces Ferry Rd Se Ste 460, Atlanta, GA 30339 Phone: 678-556-4950 | |
Mary E. Bergh, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 980 Johnson Ferry Rd Ste 520, Atlanta, GA 30342 Phone: 404-303-3320 Fax: 404-303-3464 | |
John J Doran, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1365 Clifton Rd Ne Bldg A, The Emory Clinic - Nephrology, Atlanta, GA 30322 Phone: 404-778-5380 | |
Frank A Anania, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1365 Clifton Rd Ne Ste B1266, The Emory Clinic - Gastroenterology, Atlanta, GA 30322 Phone: 404-778-3184 |